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Cardiovascular atherosclerotic events are the leading cause of mortality worldwide1 and arise most frequently 
from coronary plaque disruption, which can trigger acute myocardial infarction and sudden cardiac death2. 
Despite our current knowledge of inflammatory and immune processes in atherogenesis, the early detection 
of vulnerable plaques and the ability to predict plaque rupture in susceptible patients remain an unmet need in 
clinical practice3,4. Although currently available intravascular imaging modalities enable in vivo characterization 
of morphological parameters of atheroma plaques, they have failed to demonstrate their relevance in preventing 
acute cardiac events5–8.
Near-infrared fluorescence (NIRF) is an innovative high-resolution imaging technology that allows visualiza-
tion of inflammatory processes at the cellular level using target-specific labeled tracers, thus enabling atheroscle-
rosis detection at early stages of the disease9–11. The concept of using specific site-targeted contrast agents for in 
vivo detection of vascular pathology was previously demonstrated in a canine arterial thrombi model using ultra-
sonic contrast agent12,13. In the past decade, NIR-fluorescence catheters have been developed for intravascular 
imaging that could enable in vivo detection of high-risk coronary plaque biomarkers and, consequently, optimize 
patient stratification and clinical management14–20. The current limitations to the clinical translation of NIRF 
imaging include the lack of clinically approved tracers that target specific features of plaque biology due, in part, 
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to the weak sensitivity to molecular imaging agents, risk of toxicity from systemic administration, costs, labeling 
and regulatory issues21. Indocyanine green (ICG) and methylene blue are near-infrared fluorophore approved 
by the U.S. Food and Drug Administration (FDA) and have been used for NIRF imaging in both preclinical and 
clinical studies. Although Verjans et al.22 demonstrated ICG deposition in carotid plaque specimens from five 
patients using ex vivo intra-arterial dual-modal optical coherence tomography (OCT) – NIRF imaging, results 
showed less specific binding of the fluorophore to human plaque macrophages and lipids by comparison to pre-
vious data published from rabbit atherosclerotic plaques23. The discrepancy of ICG specificity observed between 
rabbits and human atherosclerotic plaque components could result from the short systemic half-life of ICG and 
the low concentration administered to subjects prior to endarterectomy22.
This preliminary study aimed at overcoming the present limitations of NIRF imaging and addressing the need 
for a clinically available intravascular molecular imaging modality to accurately and safely target both inflamma-
tion and specific atherosclerotic plaque components, an unmet need in clinical practice. Accordingly, the feasi-
bility of a technique of local delivery of imaging agents was evaluated using two newly engineered near-infrared 
labeled molecular probes to image plaque composition and inflammation using a custom bimodal intravascular 
ultrasound (IVUS) – NIRF imaging catheter system in atherosclerotic rabbit aortas.
Results
Fifteen male New Zealand White (NZW) 
rabbits underwent balloon denudation in the distal abdominal aorta (40-mm length), followed by a 12-week 
high-cholesterol diet (0.5% cholesterol). In vivo IVUS-NIRF imaging was performed at week 12 following local 
delivery of labeled NIRF molecular agents targeting ICAM-1 and unpolymerized type I collagen at the injured 
site of the abdominal aorta (Fig. 1). In order to perform accurate local delivery of targeted molecular probes at 
the site of the injured abdominal aorta, conventional angiography of the distal aorta was performed to locate 
the aorto-iliac bifurcation for precise porous-balloon catheter positioning. Figure 2 shows an example of NIRF 
signal colocalization following local delivery of the collagen-binding peptide probe in the distal abdominal aorta 
of a diseased rabbit aorta. Figure 2a demonstrates the angiographic location of the balloon injury region (red 
square) in the distal part of the abdominal aorta, which was the site of local infusion of the molecular imaging 
agent. Following in situ delivery of the imaging tracer, the rabbit aorta was imaged using intravascular IVUS-
NIRF imaging that enabled colocalization of in vivo NIRF signal with atherosclerotic plaque identified by IVUS 
(Fig. 2b). We observed that in vivo NIRF signal location obtained with the dual-mode imaging catheter matched 
accurately the signal obtained by ex vivo fluorescence reflectance imaging (FRI) imaging of the aorta (Fig. 2c,d). 
The fluorescence signal was stronger in lipid-rich segments of the aorta, as shown on white light image (Fig. 2e). 
Staining analysis from sections harboring atheroma plaques revealed that collagen-binding peptide fluorescence 
colocalized with collagen-rich plaques, as shown on Masson’s trichrome staining (Fig. 2f).
Ex vivo
Balloon denudation of rabbit abdominal aortas, in addi-
tion to atherogenic diet, led to the formation of lipid-rich atheroma plaques, as shown on histopathology sections 
(Fig. 3a). Staining analysis showed the presence of collagen (on Trichrome Masson’s staining) in inflamed plaques, 
as demonstrated by the presence of Oil Red O (ORO)-positive lipid plaques and neointima (on Hematoxylin and 
eosin staining). Prior to performing in vivo NIRF imaging in experimental atherosclerosis, we confirmed that 
both NIR-fluorescent molecular probes reacted with antigens in atherosclerotic aorta sections of hypercholes-
terolemic rabbits. Figure 3b shows focal staining of ICAM-1 localized in the intima of the aorta (merged image), 
by comparison to very weak signal obtained with the control sdAbs (Fig. 3d). Specific binding of the labeled 
nanobodies to ICAM-1 at the surface of cellular membranes rather than in the cytoplasm in tumor-necrosis 
Figure 1. Atherosclerotic rabbit model. At week 0, 15 male NZW rabbits of 12–13 weeks of age underwent 
balloon denudation of the distal abdominal aorta (40-mm length), upstream of the aorto-iliac bifurcation. At 
recovery, they were fed with a high-cholesterol diet (HCD) (0.5% cholesterol) over a period of 12 weeks. In 
vivo imaging experiments were performed at week 12, which consisted in performing local delivery of labeled 
NIRF molecular probes (0.04–0.46 mg/kg/probe) using a porous-balloon catheter at the site of the injured 
aorta. Immediately after local probe infusion, in vivo IVUS-NIRF imaging was acquired and repeated every 
10-min for 40 minutes (total of 5 pullbacks/rabbit). Following in vivo imaging, ex vivo fluorescence imaging and 
histopathology were performed.
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factor alpha (TNF-α) activated human umbilical vein endothelial cells (HUVEC) was previously demonstrated24. 
Diffuse staining of collagen with the collagen-binding peptide was observed in both the intima and media of 
rabbit atherosclerotic aorta (Fig. 3c) and staining with the control collagen-peptide probe was negative (Fig. 3e).
in vivo local 
We assessed blood clearance of both molecular agents and 
their controls following in situ injection at the balloon-induced injury area of rabbit abdominal aorta. Serial hepa-
rinized blood samples were taken from the sheath catheter immediately following local delivery of the NIRF probes 
using a porous balloon and every 10 minutes to perform ex vivo fluorescence imaging quantification. The blood 
clearance kinetics of both anti-ICAM-1 sdAbs (Fig. 4a) and collagen-binding peptide probes (Fig. 4b) demon-
strate a rapid systemic decline during the initial 30 minutes, which begins to stabilize at 40 minutes. There was no 
difference in blood kinetics between the molecular agents and their respective controls. Moreover, simultaneous 
dual-probe delivery did not alter the systemic clearance of the imaging agents by comparison to single-probe 
delivery (data not shown). Following local delivery of the imaging tracers, the first pullback performed using the 
IVUS-NIRF catheter detected a strong saturated NIRF signal in vivo that rapidly declined in the first 20 minutes for 
both probes, followed by a re-increase in signal intensity between 20 to 40 minutes, by comparison to a continuous 
slow decline of signal intensity of the control probes (Fig. 4c,d). The absence of binding of the control tracers to 
the arterial wall resulted in a continuous drop in signal intensity at every time-point that was then undetectable at 
45 minutes. The specific binding of molecular tracers to atheroma plaques generated a strong NIRF signal of varia-
ble intensity that could be accurately imaged by the intravascular imaging catheter after 40 minutes.
in vivo and ex vivo -
 
Intravascular imaging was safely performed in all 13 atheromatous rabbits. As both ICAM-1 and unpolymer-
ized type I collagen specific probes bind to rabbit atherosclerotic plaques, we evaluated the feasibility of local 
injections of these tracers to locate plaque in diseased animals as a potential novel modality for accurate and 
Figure 2. NIRF molecular imaging of unpolymerized type I collagen in atherosclerotic balloon injured 
rabbit abdominal aortas. Collagen-binding hairpin peptide was injected locally (0.04 mg/kg) in the balloon-
injured distal abdominal aorta of atherosclerotic rabbits after 12 weeks of 0.5% cholesterol-enriched diet. (a) 
Shows conventional angiography of the rabbit aorta with the red box indicating the balloon-injured area; (b) 
Represents IVUS imaging cross-sections of the aorta at two distinct pullback distances from the aorto-iliac 
bifurcation (27.7 mm and 41.6 mm, respectively). Red arrows delineate eccentric atherosclerotic plaques on 
IVUS imaging, which are colocalized with higher NIRF signal intensity (orange/red, outer color spectrum); (c) 
Shows in vivo intravascular NIRF imaging pullback of collagen-binding peptide probe localization in the rabbit 
abdominal aorta performed 40 minutes after local injection of the NIRF labeled agent; (d) Demonstrates ex vivo 
en face fluorescence of collagen-binding peptide over the entire rabbit aorta performed 60 minutes after local 
injection of the NIRF labeled agent. There are two distinct zones of higher NIR-fluorescence signal intensity 
seen on either in vivo and ex vivo NIRF imaging, localized mostly upstream of the injection area (c–e) Shows 
the corresponding white light image of the rabbit aorta with the red box indicating the balloon injured area. 
The distinct zones of higher NIRF signal displayed on both in vivo and ex vivo images appear to be localized 
in a lipid-rich plaque area (bright white areas); (f) Correlation histopathology of unpolymerized collagen in 
the distal abdominal aorta following staining with Masson’s trichrome (MTRI). In vivo NIRF color scale is in 
arbitrary units (yellow/white: higher NIRF signal intensity; red: lower NIRF signal intensity). Ex vivo NIRF 
color scale displays number of counts according to signal intensity (yellow/white: higher NIRF signal intensity; 
red: lower NIRF signal intensity).
4SCIENTIFIC REPORTS |          (2019) 9:2670  | 
www.nature.com/scientificreportswww.nature.com/scientificreports/
Figure 3. Ex vivo binding of NIRF molecular probes targeting ICAM-1 and unpolymerized type I collagen 
to atherosclerotic lesions in rabbit aortas. Atherosclerotic rabbit model. (a) Shows histopathology staining of 
rabbit denudated aorta sections. Left panel represents neointima staining with hematoxylin and eosin (H&E); 
mid-panel represents neutral lipids staining with Oil red O (ORO); right panel represents collagen staining 
with Masson’s trichrome (MTRI). All images are at x4 magnification. Cryosections from atherosclerotic rabbit 
aorta were stained with: (b) anti-ICAM-1 sdAbs; (c) collagen-binding peptide; (d) anti-ICAM-1 sdAbs control 
antibody and; (e) collagen-binding control peptide. The right panel shows fluorescence signal from either 
molecular probe targeting ICAM-1 or unpolymerized type I collagen, or the negative control probes. The left 
panel shows a merged image of both DAPI and the fluorescent molecular probes. The cell nuclei (blue) were 
stained with DAPI (4′,6-Diamidino-2-Phenylindole,Dilactate).
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safe catheter-based NIRF detection. In order to determine the optimal timing for NIRF imaging, dual-modal 
intracoronary IVUS-NIRF imaging was performed serially following local delivery of molecular probes over a 
40-minute period. Based on in vivo fluorescence signal stability, IVUS-NIRF imaging analysis acquired at 40 min-
utes revealed focal NIRF signals within the injured zone following either single (Fig. 5a–d) or dual-tracer infusion 
(Fig. 5e,f). Specific probe-labeling using IR800CW and Alexa-660, distinct fluorophores with different emission 
wavelength properties, enabled dual-probe injection and in vivo and ex vivo NIRF signal differentiation in a single 
diseased animal. Immediately after in vivo IVUS-NIRF imaging, fluorescence reflectance imaging of resected aor-
tas was performed and revealed NIRF activity predominantly in lipid-rich regions visible in white light images of 
atheroma-bearing aortas, whereby signal intensity tended to correlate with plaque burden. Interestingly, focal and 
diffuse NIRF signals from non-injured lipid-rich arterial segments were observed in the collagen probe-injected 
atheroma rabbits. Concordance between in vivo and ex vivo NIRF signal location was evaluated by compar-
ing NIR-fluorescence signal on intravascular imaging pullbacks and resected aortas using anatomic landmarks, 
whereas results are displayed with a shift between fluorescence signals due to postmortem tissue shrinkage (aver-
age of 25–30%). In vivo and ex vivo NIRF signals accurately matched in all rabbits for both labeled-specific tracers 
(Fig. 5a,b,e). By contrast, there were no NIRF signals detected in the control-injected groups (Fig. 5c,d,f), except 
in 2 collagen probe-injected diseased animals that showed NIRF signal in high-density plaque regions upstream 
from the injection site (thoracic and abdominal aorta). For the ICAM-1 targeted probe, the in vivo peak NIRF 
signal was 1,47-fold greater than the control (1.47 ± 0.22 versus 1.00 ± 0.05; P = 0.032; Fig. 5g) and ex vivo peak 
NIRF signal was 4.9-fold greater than the control (4.94 ± 1.73 versus 1.00 ± 0.71; P = 0.032; Fig. 5g). By contrast, 
in vivo peak NIRF signal for the unpolymerized type I collagen targeted peptide probe was 3.9-fold greater than 
the control (3.96 ± 1.07 versus 1.00 ± 0.03; P = 0.036; Fig. 5h) and ex vivo peak NIRF signal was 2.3-fold greater 
than the control but not statistically significant (2.31 ± 1.30 versus 1.00 ± 0.74; P = 0.286; Fig. 5h).
Immunostaining analysis was performed to further validate colocalization of NIRF sig-
nal of ICAM-1 on endothelial cells in atheroma plaques following local infusion of anti-ICAM-1 sdAbs imaging 
tracer. Fig. 6 shows strong NIRF signal with confocal microscopy in the balloon-induced injured area of aortas 
following anti-ICAM-1 sdAbs colocalization with mouse anti-rabbit ICAM-1 monoclonal antibody (red NIRF 
Figure 4. Blood clearance of molecular probes in atherosclerotic rabbits. Clearance from the blood of: (a) 
anti-ICAM-1 sdAbs (red squares) and the corresponding negative control (blue circles) from (n = 5/group) 
and; (b) collagen-binding peptide (red squares) and the corresponding negative control (blue circles) (n = 5 in 
the collagen group; n = 4 in the control group). Blood clearance kinetics shows a continuous decrease in NIRF 
signal intensity, which tends to stabilize 40 minutes after in vivo local injection of all NIR-fluorescence molecular 
agents. In vivo fluorescence signal detected by IVUS-NIRF catheter of both (c) anti-ICAM-1 sdAbs (red squares) 
and (d) collagen-binding peptide, by comparison to their negative controls (blue circles). Both imaging probes 
shows an initial strong NIRF signal that decreases rapidly, followed by a re-increase in signal intensity between 
20–40 minutes, mostly seen with anti-ICAM-1 sdAbs. By contrast, a weak fluorescence signal is observed for both 
negative controls following in vivo local injection in the injured zone, which then becomes undetectable after 
45 minutes. Data points are mean ± standard error of the mean (SEM) from the rabbits combined.
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Figure 5. Comparison of in vivo and ex vivo near-infrared fluorescence (NIRF) imaging of targeted ICAM-1 
and collagen in atherosclerotic rabbit aortas. Comparison of in vivo NIRF imaging and ex vivo fluorescence 
signal following single-probe local injection of either: (a) anti-ICAM-1 sdAbs, (b) collagen-binding peptide, (c) 
ICAM-1 negative controls; (d) collagen negative control; (e) dual-probe local injection of anti-ICAM-1 sdAbs 
combined to collagen-binding peptide probe, or (f) the combined negative controls. In vivo and ex vivo signals 
were colocalized in both single- and dual-probe injections along the longitudinal direction and delineated by 
white dot lines. In vivo and ex vivo fluorescence signals were properly aligned, taking into account post-mortem 
average tissue shrinkage estimated between 25–30%. In both groups, NIRF signal was only detected over the 
balloon-injured zone with the anti-ICAM-1 sdAbs agent (a,e). However, fluorescence signal was observed 
upstream from the injection zone with the collagen-binding peptide probe, notably in an aneurysm lipid-rich 
area of the aorta, as shown in (b,e). There were no NIRF signals detected in the control-injected groups (c,d,f), 
except in the abdominal and thoracic aorta of 2 rabbits following dual-injection of the control collagen-specific 
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signal), and subsequent incubation with goat anti-mouse IgG1 cross-absorbed secondary antibody (merge image, 
yellow NIRF signal).
Discussion
In the present study, we demonstrated the feasibility of local delivery of relatively small quantities of NIRF tar-
geted tracers for in vivo imaging of both morphological and biological biomarkers of atherosclerotic plaques 
using a fully-integrated real-time intravascular bimodal IVUS-NIRF imaging catheter. This preliminary study 
describes an application using in vivo molecular agents for invasive imaging of both inflammation and atheroma 
plaque components that could be translatable for future detection of high-risk human coronary artery plaques.
In vivo NIRF catheter signal detection was obtained following in situ delivery of molecular agents targeting 
either ICAM-1 or unpolymerized type I collagen in the balloon-induced injured area of the distal abdominal 
aorta of rabbits, as well as upstream of the injected region with the collagen-binding peptide agent. In vivo NIRF 
signals colocalized with atherosclerotic plaques visualized by IVUS, and signal intensity correlated with plaque 
burden. The use of a microporous-balloon catheter for in situ fluorescent probe injection, as well as repeated in 
vivo IVUS-NIRF imaging pullbacks in a single animal, demonstrated the feasibility and safety of the technique 
and enabled determination of NIRF molecular imaging probe kinetics for optimal in vivo catheter-based imaging. 
The use of a low-pressure microporous balloon-catheter system confers the advantage of both bringing imaging 
probes in contact with the intima, while avoiding plaque disruption or vessel trauma from its semi-compliant 
properties that eluded balloon over-expansion. Moreover, performing proper balloon sizing to vessel diameter 
by QCA prior to local infusion renders this technique suitable for translational applications in future studies. 
The absence of in vivo NIRF signal at the vicinity of atheroma plaques following injection of specific negative 
controls further validated the specificity of fluorescence signal obtained with both ICAM-1 and unpolymerized 
type I collagen targeted imaging tracers. These findings were then confirmed by matching the whole rabbit aorta 
fluorescence reflectance imaging ex vivo with in vivo NIRF signal detected by intravascular NIRF, which showed 
signal colocalization in all rabbits with respect to both molecular imaging agents.
In vivo imaging tracer kinetics were analysed following multiple pullbacks performed at different time points 
using a custom dual-imaging catheter. Differences observed between in vivo clearance kinetics of molecular tracers 
and their controls could be the result of both tracer’s initial local diffusion of bounded probes on plaque surface, 
along with systemic clearance of unbound probes, leading to an initial decrease in signal intensity. A subsequent 
increase in fluorescence signal observed with both target-specific tracers in the aftermath of additional binding 
of the probes from systemic circulation/redistribution was seen, more predominantly with anti-ICAM-1 sdAbs, 
reaching a state of stability between 40 to 50 minutes. It is plausible that the peptide collagen probe diffused more 
easily in the plaque than ICAM-1 nanobodies immediately following local delivery and thus a faster saturation of 
the ligands was observed. Moreover, from the ex vivo imaging of the whole rabbit aortas, we’ve observed focal and 
diffuse NIRF signal from non-injured lipid-rich arterial segments, mostly in the thoracic aorta, which may explain 
less redistribution of the peptide probe at sites of the injured lipid plaques in subsequent imaging time points. 
Nevertheless, pharmaco-kinetic properties of both imaging tracers enable targeting diseased arterial segments 
prior to achieving a steady state, which makes them valuable for future studies in atherosclerosis imaging.
Numerous fluorophore-coupled imaging probes targeting a variety of molecular biomarkers have been previ-
ously tested in atherosclerotic animal models for intravascular imaging, including matrix metalloproteinases25,26, 
macrophages23,26, cathepsins14–16,26–28 and oxidized low-density lipoproteins (oxLDL)29. Systemic administration 
of a prespecified dosage of these imaging compounds several hours prior to in vivo and/or ex vivo imaging was 
performed to allow fluorescent probe diffusion in the atheroma plaques. Indocyanine green was also used as a 
fluorescent probe in experimental animal models (10 mg/kg in rabbits) and humans (0.25–2 mg/kg) for the assess-
ment of high-risk plaques following intravenous injection of safe doses17,18,22,23. By contrast, our study demon-
strated the feasibility and reliability of specific in vivo NIRF signals following local delivery of a concentration 6–50 
times less than the intravenous dosage of molecular fluorescent tracers (0.04–0.4 mg/kg), with the advantages of 
avoiding potential risk of adverse effects or immune reactions from systemic administration, suboptimal biodis-
tribution and tracer diffusion in regions of interest. As shown in atherosclerotic rabbits following local injection 
of the collagen-peptide probe, in vivo NIRF signals were observed not only in the balloon-induced injury area 
but also in several lipid-rich regions of the aorta. This suggests that the use of another vector for selective in vivo 
probe delivery for future studies in coronary arteries could enable accurate imaging of biological biomarkers of 
surrounding atheroma plaques while avoiding the relative risk of vascular injury or compromising blood flow from 
in situ tracer delivery. The injection through a 6 F guiding catheter could be a plausible alternative however would 
enable a semi-selective injection of tracers rather that a local selective infusion in the region of interest. Perhaps 
the use of a microcatheter or thrombectomy catheter available in the catheterization laboratory would convey the 
injection of imaging probes at the vicinity of the plaque, thus render a more selective injection without the risk of 
ischemia or plaque disruption. From a translational standpoint, this technical application could certainly outweigh 
the limitations of conventional angiography in ascertaining the true extent of disease in the arterial wall, and for 
better assessment of non-flow limiting coronary stenoses harboring features of plaque instability.
agent. In vivo and ex vivo peak NIRF signal in: (g) ICAM-1 probe- and (h) collagen-peptide probe injected 
abdominal aortas. White dot lines indicate the injury zone of the distal abdominal aorta, site of molecular 
probes delivery through the porous-balloon catheter. In vivo NIRF color scale is in arbitrary units (yellow/
white: higher NIRF signal intensity; red: lower NIRF signal intensity). Ex vivo NIRF color scale displays number 
of counts according to signal intensity (yellow/white: higher NIRF signal intensity; red: lower NIRF signal 
intensity). Scale bar: 10 mm. Data is presented as mean ± standard error of the mean (SEM).
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A postmortem study revealed that plaque rupture was by far the most frequent cause of atherothrombo-
sis, accounting for two-thirds of sudden cardiac deaths and more than 65% of acute myocardial infarctions30. 
Rupture-prone plaques are defined by a large lipid-rich necrotic core with an overlying thin fibrous cap infiltrated 
with macrophages and lymphocytes. The vulnerable plaque, or so-called thin-cap fibroatheroma (TCFA), is sub-
jected to factors that can alter plaque morphology and thus lead to plaque instability and rupture30,31. Although 
the PROSPECT (Providing Regional Observations to Study Predictors of Events in the Coronary Tree) study 
identified specific morphologic predictors of lesion progression in non-culprit plaques at 3 years assessed by 
virtual histology (VH-IVUS)5, findings that were further supported by the VIVA (VH-IVUS in Vulnerable 
Atherosclerosis) and ATHEROREMO-IVUS (European Collaborative Project of Inflammation and Vascular Wall 
Remodeling in Atherosclerosis-Intravascular ultrasound) studies6,8, plaque morphology and composition alone 
do not accurately predict which non-culprit plaques will cause recurrent adverse cardiac events. Thus, routine 
use of invasive imaging to screen for vulnerable plaques and to predict the risk of cardiovascular complications is 
currently proscribed32. This reinforces the potential of imaging active biological processes to provide new insights 
on atheroma plaque growth, healing and biomarkers involved in plaque instability. In the present study, ICAM-1 
and unpolymerized type I collagen were the selected biomarkers for in vivo molecular imaging of both inflam-
mation and plaque morphology. With the knowledge that ICAM-1 is involved in plaque formation and pro-
gression, while collagen, a major constituent of atheroma plaque, undergoes proteolysis and is less produced by 
smooth muscle cells (SMC) in high-risk plaques, the quantification of both biomarkers by IVUS-NIRF imaging 
could enable characterization of plaque morphology and harbor the potential to discriminate between stable and 
unstable plaques at risk of rupture, along with other inflammatory biomarkers. We have demonstrated that dual 
injection of molecular probes coupled with tracers harboring different excitation and emission wavelength prop-
erties enabled accurate NIRF signal discrepancy in a single animal. Perhaps the combination of several biological 
fluorescent agents, along with plaque morphology assessed by catheter-based technology (IVUS or OCT), may 
be an attractive avenue for identifying in vivo high-risk plaques in future studies.
The current study describes a reliable technique for imaging specific features of atherosclerotic plaques using 
local delivery of labeled specific molecular tracers followed by intravascular IVUS-NIRF imaging. Although this 
proof-of-principle study using novel molecular imaging probes is promising for identifying both structural and 
biological properties of atherosclerotic plaques, these preliminary findings should be validated in a longitudi-
nal study using a larger animal model that features coronary atheroma with a phenotype more similar to that 
observed in humans (e.g. swine). Such studies may provide new insights on plaque inflammation at early stages 
of the disease. Given that both ICAM-1 and unpolymerized type I collagen have not yet been established as being 
indicative of plaque rupture and thrombotic complications, the application of this imaging methodology using a 
combination of newly designed tracers targeting these biomarkers could pave the way for a better understanding 
of the pathophysiology of high-risk atheroma plaques and disease progression, especially the contributions of 
plaque inflammation and tissue (collagen) remodeling, and may allow to develop future targeted therapies (per-
sonalized medicine).
Limitations
Notwithstanding that this study demonstrates the feasibility of in vivo labeled tracer-based IVUS-NIRF intravas-
cular molecular imaging as a method for detection of inflamed atherosclerotic plaques, there are several limita-
tions to be mentioned. First, we were unable to conduct correlation analysis of quantified NIRF signal between 
in vivo and ex vivo fluorescence signal detected in rabbit aortas due to the small sample size. Second, despite 
in vivo and ex vivo blood clearance kinetics analyses of both molecular agents for optimal timing of in vivo 
catheter-based imaging, their diffusion properties from plaque surface remain unknown. Since a single con-
centration of all tracers was tested in the present study, it remains to be determined whether a lower dose using 
the same administration method would provide sufficient NIRF enhancement for in vivo catheter-based signal 
detection. In addition, in vivo imaging was performed at different time-points over a 40-minute period and, from 
the late resurgence in signal intensity detected by the imaging catheter in vivo for both probes, the optimal timing 
for intravascular imaging may be beyond this timeline. In vivo NIRF signal was obtained with 2 collagen negative 
control probes in lipid-rich regions of the aorta, which probably was a result of nonspecific binding of the tracer 
Figure 6. Immunostaining validation of anti-ICAM-1 sdAbs in atherosclerotic rabbit aortas. Colocalization of 
ICAM-1 in atherosclerotic rabbit aorta by immunofluorescence. Anti-ICAM-1 sdAbs NIRF signal colocalize 
with ICAM-1 on endothelial cells by staining the sections with primary mouse anti-rabbit ICAM-1 monoclonal 
antibody (red NIRF signal, images 1 and 2), followed by a secondary labeling using goat anti-mouse IgG1 
antibody (green NIRF signal, image 3), The merged image shows specific colocalization of ICAM-1 on 
endothelial cell surface of atherosclerotic aorta segments (yellow NIRF signal, image 4). The endothelial cell 
nuclei (blue) were stained with DAPI (image 5). No autofluorescence signal was detected under confocal 
microscopy (image 6).
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to plaque surface which may bear an endothelial surface more permeable than non-diseased regions. Another 
limitation is the large diameter of the current bimodal IVUS-NIRF imaging catheter prototype due to the rigid 
optic fiber, which limited catheter-to-wall distance in rather small diameter distal abdominal aortas. Nevertheless, 
further optimization of catheter dimensions and flexibility, in addition to the validation of this novel imaging 
technique in a porcine atherosclerotic model with plaque biology more similar to human fibroatheroma plaques, 
will be required to overcome these limitations.
Methods
The atherosclerotic plaque model was generated by per-
forming balloon denudation in the distal abdominal aorta of 15 male New Zealand White rabbits (3 kg, aged 
12–13 weeks; Charles River Laboratories, Saint-Constant, QC, Canada) at week 0. Rabbits were then placed on a 
cholesterol-enriched diet (0.5% cholesterol, Harlan Teklad Diets, Madison, WI) for 12 consecutive weeks (Fig. 1). 
The experimental protocol was approved by the animal ethics committee of the Montreal Heart Institute Research 
Center according to the guidelines of the Canadian Council on Animal Care.
Under continuous anesthesia (aceprozamine (1 mg/kg intramuscular (IM)), 
buprenorphine (0.01 mg/kg IM) and inhaled isoflurane (4% v/v, Baxter, Deerfield, IL)), a 5 French (F) sheath cath-
eter (Cordis Corporation, Miami, FL, USAs) was used to cannulate the right carotid artery. Baseline angiography 
of the abdominal aorta (Siemens, Germany) was performed using a 5 F right Judkins (JR) 4.0 guiding catheter 
(Cordis Corporation, Miami, FL, USA) inserted into the aorta over a 0.014-inch guidewire (Abbott Vascular, 
Santa Clara, CA). The minimal lumen diameter (MLD) of the abdominal aorta, measured on an end-diastolic 
frame by quantitative coronary analysis (QCA; Syngo software, ARTIS Siemens, Germany), was used for accurate 
PTCA balloon sizing. Under fluoroscopic guidance, balloon injury was performed in the distal 40-mm of the 
abdominal aorta using a standard PTCA balloon-catheter (Boston Scientific, Marlborough, MA), corresponding 
to a balloon/artery ratio of 1.1 to 1.2:1, that was inflated at 10 atm for 30 seconds over three consecutive times, 
with 30-second intervals between inflations. After balloon denudation, the sheath catheter was removed, and the 
right carotid artery was ligated. Post-operative care consisted in strict monitoring of the vital signs and animal 
behavior. Analgesia was managed by subcutaneous administration of buprenorphine (0.02 mg/kg) and ketopro-
fen (2 mg/kg) immediately after the procedure and on day 1 (2 doses). Post-operative infection management 
consisted in a prophylactic dose of Borgal (67 mg/kg) administered subcutaneously immediately after the surgery 
combined to a sterile dressing applied on the surgical wound, with daily surveillance of the surgical sutures.
Anti-ICAM-1 VHH single-domain antibody (sdAb) or nano-
bodies were generated by immunizing a male lama. A VHH library was constructed and panned as described 
before29. After four rounds of panning against recombinant human ICAM1 (R&D systems), ICAM-specific 
VHH were identified by phage-ELISA. Unique VHH sequences, identified by sequencing, were sub-cloned into 
pSJF2 expression vector and the VHHs were expressed in TG1 bacteria as described before (US patent: 8,623,369 
B2)29. The ICAM-1 sdAbs were purified by IMAC column and size-exclusion chromatography (SEC), and their 
binding affinities were determined by surface plasmon resonance (SPR)29. The SEC-purified sdAbs were labeled 
with IRDye® 800CW (LI-COR Biosciences, MA, USA) infrared dye for NIRF imaging. An ELISA was used to 
confirm functional reactivity of ICAM-1 sdAb before and after labeling. Briefly, wells of a Nunc96 plate were 
coated with the recombinant human ICAM and blocked with Strating Block (Thermo Scientific). Serial dilution 
of sdAbs were added to the wells and incubated for 1 hour at room temperature. Specific bindings of sdAbs were 
detected by rabbit anti-His tags-HRP conjugate (Bethyl lab), the color was developed by adding KPL substrate 
(KPLGaithersburg, MD) and the plate was read at 450 nm33. As controls, wells with no antigen (blank) and coated 
by ICAM-1 but used a nonrelated VHH were included in the assay.
This probe was derived from a collagen-binding hair-
pin peptide GEWTWDDATKTWTWTE that targets specifically unpolymerized type I collagen (US patent pub-
lication: 2016/0168210 A1). The peptide portion of this probe GEWTWDDATKTWTWTEGGC was purified 
using HPLC from materials obtained by solid-phase peptide synthesis (SPPS) and labeled via the Cys residue with 
Alexa-660-monomaleimide (Thermo Fisher Scientific, MA, USA) infrared dye for NIRF imaging. A negative con-
trol peptide ETVTFTKTADDYTSEGGGC was derived from a non-binding peptide GEWTYDDATKTFTVTE 
(US patent publication: 2016/0168210 A1) with the Trp (W) residue replaced by Ser followed by sequence rever-
sal. The control peptide was also conjugated to Alexa-660-monomaleimide. Both probes were further purified 
using HPLC after Alexa-660 conjugation and dried to powders before reconstitution in physiological saline. Final 
concentrations of the peptide probes were determined by use of the dry weight of the peptide powders.
Cryosections from rabbit atherosclerotic aortas were used to test 
the reactivity of both the anti-ICAM-1 sdAb and unpolymerized type I collagen peptide probes, with their respec-
tive negative controls, by ex vivo fluorescence microscopy. Cryostat sections of 8 μm were obtained and incubated 
with 10 μg/ml of either probe for 2 hours at room temperature. Images were taken at 20x with a confocal micro-
scope Zeiss LSM 7 Duo (Carl Zeiss Microscopy GmbH, Göttingen, Germany) with filter sets for Alexa-660 and 
IR800CW fluorescence signal detection (excitation/emission, 633/641–759 nm).
In vivo  
The 5 F compatible custom-made imaging catheter used in this study has been previously described34,35. The 
catheter combines a 400 μm optical fiber that enables 360-degree fluorescence imaging and photoacoustic excita-
tion, and an ultrasound transducer (extracted from the commercially available IVUS 45 MHz Revolution cath-
eter; Volcano Therapeutics, Rancho Cordova, CA) for acoustic imaging and photoacoustic signal detection. The 
1 0SCIENTIFIC REPORTS |          (2019) 9:2670  | 
www.nature.com/scientificreportswww.nature.com/scientificreports/
catheter has a diameter of 1.4 mm and is connected to an electronic circuit that enables synchronized acquisitions 
of fluorescence and IVUS imaging modalities from rotating pullbacks at an angular speed of 30 revolutions/
second. The pullback speed was set to 0.5 mm/second and the frame rate was 10 images/seconds, with a total 
pullback length of 100 mm. Raw data is transferred to a computer bearing a custom Matlab (The MathWorks, 
Inc., Natick, MA) user interface that filters the signals, reconstructs, and displays the images in real time during 
acquisition. This single IVUS-NIRF system enable to interchange lasers and filters according to the fluorophore 
properties to be imaged. Fluorescence excitation was performed using either a 730-nm laser diode for IR800CW 
labeled probe or a 660-nm laser diode for Alexa-660 labeled probe. We’ve measured Alexa-660 with the 800-nm 
channel and IR800CW with the 660-nm channel with the imaging catheter and no bleed-through was detected. 
Emission was detected by a photomultiplier tube (Hamamatsu Photonics, Hamamatsu City, Japan) combined to 
either a 776-nm longpass filter (IR800CW) or a 716 ± 20 nm filter (Alexa-660).
In vivo Of the 15 animals, two died after bal-
loon denudation and were excluded; 13 animals were used to perform in vivo imaging procedures at week 12. 
Under general anesthesia, a 5 F sheath catheter (Cordis Corporation, Miami, FL, USA) was used to cannulate 
the left carotid artery. Under fluoroscopic guidance, molecular probes were injected at the injured site of the 
distal abdominal aorta upstream from the aorto-iliac bifurcation using a 20-mm-long semi-compliant micro-
porous balloon catheter (ClearWayTM RX, Atrium Medical, New Hampshire, USA)36 inserted over a 0.014-inch 
guidewire (Abbott Vascular, Santa Clara, CA). Administration dosage for the collagen-targeting probe was 0.07–
0.12 mg per rabbit (formulated in an infusion volume of 2.5 ml), which was set according to the probe dosage of 
0.25–0.5 mg/kg/probe in rat or mouse systemic biodistribution studies (US patent publication: 2016/0168210 A1). 
The anti-ICAM-1 sdAb dosage was 0.4 mg/kg per rabbit. Accurate porous-balloon catheter sizing (balloon/artery 
ratio of 1.1 to 1.2:1) was determined by the minimal lumen diameter (MLD) of the abdominal aorta measured on 
an end-diastolic frame by quantitative coronary analysis (QCA; Syngo software, ARTIS Siemens, Germany). The 
infusion was done over 90-sec, at 4 atm, followed by a flush of saline (1.5 mL). Seven rabbits had a single injection 
of either the probe targeting ICAM-1, unpolymerized type I collagen, or their respective negative controls at the 
injury site of the distal abdominal aorta; six rabbits had a dual-probe injection of either the combined molecular 
tracers or the combined controls. Immediately after the injection, the intravascular imaging catheter was inserted 
over a 0.014-inch guidewire and in vivo IVUS-NIRF imaging of the distal abdominal aorta was acquired every 
10 minutes over a 40-minute period. For dual-probe injection, 2 consecutive pullbacks were performed at every 
time-points with different bandpass optical filters for fluorescence detection of both tracers. A total of 5 serial 
pullbacks were performed in the same arterial segment for each rabbit, whereas the aorto-iliac bifurcation cor-
responds to the proximal anatomic landmark of the 50-mm length pullback. Blood samples were taken from the 
sheath catheter (1 mL) prior to each pullback to perform ex vivo fluorescence imaging. At the end of the experi-
ment, animals were sacrificed and the aorta was resected.
In vivo A 
dedicated blood attenuation algorithm was applied to all in vivo pullbacks, as previously described35, to com-
pensate the fluorescence signal amplitude with the distance between the imaging catheter and the arterial wall.
Ex vivo After euthanasia and saline infusion, aortas 
were resected, opened and manually elongated in a petri dish coated with black wax and filled with saline to 
perform en face FRI at 37 °C using a commercial epi-illumination fluorescence imaging system (IVIS Lumina II, 
PerkinElmer, MA, USA). The following parameters were used: Ex/Em 745 ± 20/800 nm ± 20 nm for anti-ICAM-1 
sdAbs and 640 ± 20/720 ± 20 nm for collagen-binding peptide probe, a field of view (FOV) of 10 cm, F/stop 1, 
Binning (M) 4/2, excitation time of 20 seconds. The total fluorescence values (intensity/cm2) of the region of 
interest (i.e. 20-mm injected area in the distal abdominal aorta) were analysed using a computer-based digitizing 
image system software (Lumina II Living Image 2.0). After each imaging session, the regions of interest (ROI; 
15 mm in length) were embedded in Neg-50 (Thermo Fisher Scientific, MA, USA) and preserved at −80 °C for 
further microscopy validation of the ex vivo imaging results. The average tissue shrinkage was estimated between 
25–30%, according to side branches that were used as landmarks and pullback length. For histopathology anal-
yses, several 6-μm sections were cut, and morphometry was demonstrated with Masson’s trichrome staining, 
including collagen and fibrosis quantification. Von Kossa staining was performed to identify calcium in the neo-
intima and media, and Oil red O (ORO, Sigma) to identify neutral lipids in the neointima and media.
Cryosections (10 μm thickness) were obtained from fresh-frozen rabbit 
aortas. Fluorescence microscopy of aorta sections comprised in the region of interest was performed using a Zeiss 
LSM 7 Duo microscope (Carl Zeiss Microscopy GmbH, Göttingen, Germany) that visualized the distribution of 
anti-ICAM-1 NIRF signal (Ex/Em, 638/755 nm) and anti-ICAM-1 antibody (Ex/Em, 544/649 nm). NIRF sig-
nal colocalization was performed using a mouse anti-rabbit ICAM-1 monoclonal antibody, clone Rb2/3 (kindly 
provided by Pr. Miron Cybulsky, University of Toronto, Canada). Slides were fixed for 5 minutes in acetone at 
−20 °C and incubated overnight with primary antibody at 4 °C, followed by staining with a goat anti-mouse IgG1 
cross-absorbed secondary antibody, Alexa Fluor 555 (A-21127, Invitrogen, Thermo Fisher Scientific, MA, USA).
Data are presented as mean ± SEM (standard error of the mean). Mann-Whitney test 
was used to compare peak plaque TBR between the molecular probe injection group and the control injection 
group for both in vivo and ex vivo fluorescence studies using Prism 7.0 (GraphPad Software, Sand Diego, CA). 
Values of P < 0.05 were considered statistically significant.
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Data Availability
All data generated or analyzed during this study are included in this published article.
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